SCHEMBL10058722

SCHEMBL10058722

COC(=O)c1c(-c2ccc(C(F)(F)F)cc2)cc(C)cc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.47
BACE1 P56817 1/20 0.46
CISD2 Q8N5K1 1/20 0.44
AKR1C3 P42330 2/20 0.44
AKR1C2 P52895 2/20 0.44
PTPN1 P18031 1/20 0.44
MAPT P10636 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
APP P05067 1/20 0.43
KDM1A O60341 1/20 0.42
CYP46A1 Q9Y6A2 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30755485 0.92 CFTR (0.43) CFTRBACE1CISD2AKR1C3AKR1C2
SCHEMBL10058710 0.88 NOTUM (0.51) CFTRBACE1CISD2AKR1C3AKR1C2
SCHEMBL27372936 0.86 EGFR (0.52) CFTRBACE1CISD2AKR1C3AKR1C2
SCHEMBL30755251 0.86 EGFR (0.52) CFTRBACE1CISD2AKR1C3AKR1C2
SCHEMBL6698582 0.82 CFTR (0.55) CFTRBACE1AKR1C3AKR1C2PTPN1
SCHEMBL30755410 0.79 BACE1 (0.44) CFTRBACE1CISD2PTPN1MAPT
SCHEMBL7041867 0.79 BACE1 (0.44) CFTRBACE1CISD2PTPN1MAPT
SCHEMBL5937194 0.79 CYP46A1 (0.68) CFTRBACE1AKR1C3AKR1C2PTPN1
SCHEMBL23354519 0.77 CFTR (0.63) CFTRBACE1AKR1C3AKR1C2PTPN1
SCHEMBL2267996 0.77 SLC2A1 (0.51) AKR1C3AKR1C2PTPN1KDM1ANOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114993-B2 Use of aryl chlorides in palladium-catalyzed C-H bond functionalization THE UNIVERSITY OF HOUSTON SYSTEM (US) 2012-02-14 US disclosed
US-20090012293-A1 USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION THE UNIVERSITY OF HOUSTON SYSTEM (US) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012293-A1 USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION DBH, DDT, CYCS CFTR 2800/4885BACE1 4452/4885CISD2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.